Wire · operational-macro
Hansa CEO Aguiar-Lucander: U.S. Listing Is Not Optional for European Biotech
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Hansa Biopharma's CEO states that European public markets cannot fund growth-stage biotech, making a U.S. IPO filing essential alongside the imminent FDA decision on imlifidase, a drug enabling kidney transplants in highly sensitized patients. The dual catalysts of regulatory approval and U.S. listing are necessary for market validation, capital, and commercial build-out.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 21 Aug 2026 and 2 Sep 2026.
◆ ◆ The Wire takeaway
The US public market is now the only realistic path to growth for European biotechs like Hansa. You need to plan capital and commercial strategy around US market entry, not just drug development.
◆ Coverage
3 sources · first reported 21 Aug 2026 · latest 2 Sep 2026
◆ Related on Wire
◆ Topics